Nov-Dec 2014 Issue
Partner and head of the firm’s Life Sciences Practice Cheryl Reicin provides comment in a Lexpert article on the recent rise of M&A, regulatory and capital markets opportunities in the North American life sciences sector. Below is an excerpt of the article.
The US numbers portend well for Canada, where the timing of early-stage investment is accelerating. “What’s driving the market as well is that venture capitalists and big pharma money is coming in earlier in the development cycle and the angel network in Canada is building nicely because they’re seeing good results,” says Cheryl Reicin of Torys LLP’s Toronto office.
To read the full article, click here.